Azitra (AZTR) Cash & Equivalents (2022 - 2026)
Azitra's (AZTR) quarterly Cash & Equivalents came in at $10.1 million in Q1 2026, up 213.44% YoY from $3.2 million in Q1 2025, and up 386.01% on a QoQ basis from $2.1 million in Q4 2025.
Azitra (AZTR) Cash & Equivalents (2022 - 2026) Analysis & Trends
Azitra (AZTR) has 5 years of Cash & Equivalents data on file, last reported at $10.1 million in Q1 2026.
- Quarterly Cash & Equivalents rose 213.44% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (up 213.44% YoY) and the FY2025 annual result came in at $2.1 million, down 54.59% from the prior year.
- Cash & Equivalents advanced to $10.1 million in Q1 2026, from $2.1 million in the prior quarter.
- In the past five years, Cash & Equivalents ranged from a high of $10.1 million in Q1 2026 to a low of $803082.0 in Q2 2024.
- A 5-year average of $3.8 million and a median of $3.2 million in 2025 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2024 — Cash & Equivalents sank 87.23% — and 2026, when it jumped 213.44%.
- Tracing AZTR's Cash & Equivalents over 5 years: stood at $3.5 million in 2022, then plunged by 48.58% to $1.8 million in 2023, then surged by 153.61% to $4.6 million in 2024, then slumped by 54.59% to $2.1 million in 2025, then soared by 386.01% to $10.1 million in 2026.
- The last three Cash & Equivalents figures came in at $10.1 million (Q1 2026), $2.1 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 3.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.72 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.71 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.93 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 544.80 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 811.99 Mn |
| 10 | Azitra | 2.53 Mn | 2.53 Mn | - | 6.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.73 Mn |
| Mar 31, 2026 | 10.05 Mn |
| Dec 31, 2025 | 2.07 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 3.21 Mn |
| Dec 31, 2024 | 4.55 Mn |
| Sep 30, 2024 | 7.26 Mn |
| Jun 30, 2024 | 803,082.00 |
| Mar 31, 2024 | 3.00 Mn |
| Dec 31, 2023 | 1.80 Mn |
| Sep 30, 2023 | 4.40 Mn |
| Jun 30, 2023 | 6.29 Mn |
| Dec 31, 2022 | 3.49 Mn |